Press release
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
-INPEFA® Launch Positioned for Acceleration in 2024- -Clinical Data and FDA Feedback Support INPEFA Life Cycle Management Opportunity in Hypertrophic
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":" -INPEFA® Launch Positioned for Acceleration in 2024- -Clinical Data and FDA Feedback Support INPEFA Life Cycle Management Opportunity in Hypertrophic Cardiomyopathy- -LX9211 Late-Stage Development Underway, with Potential to Be First New Non-Opioid Drug for Diabetic Peripheral Neuropathic Pain in Over Two Decades- -Company Presentation January 11, 2024 at 10:30am PST (1:30pm ET)- THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024. “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon. “We gained FDA approval in heart failure for INPEFA® (sotagliflozin), an important new drug created from our own discovery efforts, and we advanced neuropathic pain drug candidate LX9211 into late-stage development. We are working diligently to build on this success in 2024 as we focus on accelerating the launch of INPEFA, leveraging its differentiated profile and recently-adopted guidelines in the large, fast-growing and under-penetrated heart failure market, and advancing the clinical program for LX9211 in diabetic peripheral neuropathic pain (DPNP), where it has the potential to become the first, new, non-opioid drug in over two decades. We are also evaluating additional opportunities for partnership and growth including life-cycle management potential for INPEFA in hypertrophic cardiomyopathy (HCM).” INPEFA Launch Positioned for Acceleration in 2024 Lexicon continues to focus on accelerating the launch of INPEFA, having recently strengthened and evolved its commercial organization to be better placed for success with recent leadership additions and a sales force in place of approximately 150 cardiovascular specialty representatives focused on high-volume prescribers and institutions. The company’s sales force has succeeded in driving demand well ahead of filled prescriptions in 2023 pending continuing progress in establishing broader market access and reimbursement. Further improving and expanding market access and reimbursement is a key area of focu...